Condition

Pancreatic Cancer Metastatic clinical trials and research

• 17Clinical trials
• 23Countries

Newest Pancreatic Cancer Metastatic clinical trials

All recruiting trials (17)

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

• Gemcitabine plus nab‑paclitaxel with or without pitavastatin for unresectable pancreatic adenocarcinoma

  This phase 1 test looks at whether adding pitavastatin to ongoing gemcitabine‑based chemotherapy is safe and may help people with unresectable or metastatic pancreatic adenocarcinoma.

  Recruiting Phase 1 University of California, Irvine · Orange, California · NCT07549958

• Daraxonrasib alone or with gemcitabine and nab-paclitaxel for first-line metastatic pancreatic cancer

  This trial will see if daraxonrasib, alone or with gemcitabine and nab-paclitaxel, helps people with newly diagnosed metastatic pancreatic cancer live longer or slow tumor growth compared with standard gemcitabine and nab-paclitaxel.

  Recruiting at 61 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 81 other locations · NCT07491445

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

• Holistic acupuncture to reduce chemotherapy-induced nausea

  This study will test whether adding acupuncture and acupressure to standard anti-nausea medicine helps adults receiving chemotherapy who still have nausea.

  Recruiting Vejle Hospital · Vejle · NCT07201194

• EDV nanocell therapy with gemcitabine and nab‑paclitaxel for metastatic pancreatic cancer

  This trial tests whether adding EDV nanocell therapy (E-EDV-D682 with EDV-GC) to gemcitabine and nab‑paclitaxel helps people with metastatic pancreatic ductal adenocarcinoma who progressed after first-line therapy.

  Recruiting at 3 sites Phase 1/2 Engeneic Pty Limited · El Segundo, California and 3 other locations · NCT07049055

• Regorafenib with toripalimab and albumin‑bound paclitaxel for third‑line advanced pancreatic cancer

  This trial will test whether adding regorafenib to toripalimab and albumin‑bound paclitaxel helps people with unresectable or metastatic pancreatic cancer who have already received two prior lines of therapy.

  Recruiting Phase 1/2 Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center · Shenzhen, Guangdong · NCT07040228

• TNG462 combined with RAS inhibitors or chemotherapy for MTAP‑loss pancreatic and RAS‑mutant lung cancer

  This trial will test whether taking oral TNG462 together with RAS inhibitors or standard chemotherapy is safe and helps people with MTAP‑loss pancreatic cancer or RAS‑mutant non‑small cell lung cancer.

  Recruiting at 18 sites Phase 1/2 Tango Therapeutics, Inc. · Scottsdale, Arizona and 17 other locations · NCT06922591

• Carbon ion radiotherapy for pancreatic cancer treatment

  This study is testing a new treatment using carbon ion radiotherapy along with two other drugs to see if it can help people with advanced pancreatic cancer live longer and have fewer side effects.

  Recruiting Gansu Wuwei Tumor Hospital · Wuwei, Gansu · NCT06840067

• New treatment for metastatic pancreatic cancer using polymeric micelles

  This study is testing a new way to give a cancer drug for people with metastatic pancreatic cancer to see if it works better than the current standard treatment.

  Recruiting at 2 sites Phase 3 Shanghai Yizhong Pharmaceutical Co., Ltd. · Nanjing, Jiangsu and 1 other locations · NCT06752811

• Comparing surgery and palliative care for liver metastases in pancreatic cancer

  This study is testing if surgery to remove both the main pancreatic tumor and liver metastases can help people with pancreatic cancer live longer and feel better compared to just receiving palliative care.

  Recruiting Phase 2 Azienda Ospedaliera di Padova · Padova, Italy · NCT06690528

• Using medical cannabis to relieve symptoms in patients with advanced pancreatic cancer

  This study is testing if medical cannabis can help relieve symptoms like pain and nausea in people with advanced pancreatic cancer.

  Recruiting Phase 2 HealthPartners Institute · Saint Louis Park, Minnesota · NCT06605430

• Combination treatment for advanced pancreatic cancer

  This study is testing a combination of three medications with Gemcitabine to see if it can help people with advanced pancreatic cancer who haven't had much success with other treatments.

  Recruiting Phase 1/2 State University of New York - Downstate Medical Center · Brooklyn, New York · NCT06030622

• Surufatinib plus gemcitabine/nab‑paclitaxel versus gemcitabine/nab‑paclitaxel for first‑line advanced or metastatic pancreatic cancer

  This study will test whether adding surufatinib to standard gemcitabine plus nab‑paclitaxel helps people with locally advanced or metastatic pancreatic cancer who had two cycles of AG without disease progression.

  Recruiting Phase 2 Fudan University · Shanghai · NCT05969171

• Combining Nab-Paclitaxel and Gemcitabine with SBP-101 for Pancreatic Cancer

  This study is testing if adding a new treatment called SBP-101 to the standard drugs nab-paclitaxel and gemcitabine can help people with untreated metastatic pancreatic cancer live longer and feel better.

  Recruiting at 77 sites Phase 2/3 Panbela Therapeutics, Inc. · Hot Springs, Arkansas and 92 other locations · NCT05254171

Related topics

Quick answers

How many Pancreatic Cancer Metastatic clinical trials are recruiting right now?

17, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 23 countries. The most sites are in United States (10 trials), China (5 trials), United Kingdom (4 trials), Italy (4 trials), Australia (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 5, Phase 1/2: 5, Phase 2: 3, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →